MedTrace Logo

Treatment Strategy for Patients With RA-ILD

NCT07643038 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 204

Last updated 2026-06-11

No results posted yet for this study

Summary

This is a 52-week, multicenter, prospective, open-label, randomized controlled clinical study, comparing the efficacy and safety of tocilizumab, telitacicept, and csDMARD methotrexate in patients with RA-ILD.

Conditions

  • Rheumatoid Arthritis Associated Interstitial Lung Disease

Interventions

DRUG

Tocilizumab

Tocilizumab will be administered intravenously at a dose of 8 mg/kg every 4 weeks in addition to stable background csDMARD therapy maintained throughout the study period.

DRUG

Telitacicept

Telitacicept will be administered by subcutaneous injection at a dose of 160 mg once weekly in addition to stable background csDMARD therapy maintained throughout the study period

DRUG

Methotrexate

Methotrexate will be administered orally at a dose of 15 mg once weekly in addition to stable background csDMARD therapy

Sponsors & Collaborators

  • Chinese SLE Treatment And Research Group

    lead OTHER

Principal Investigators

  • Xinping Tian · Peking Union Medical College Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-01
Primary Completion
2029-07-31
Completion
2029-07-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07643038 on ClinicalTrials.gov